-
公开(公告)号:US20110144056A1
公开(公告)日:2011-06-16
申请号:US12996435
申请日:2009-06-01
申请人: Linus S. Lin , Linda L. Chang , Harry Chobanian , Ravi P. Nargund
发明人: Linus S. Lin , Linda L. Chang , Harry Chobanian , Ravi P. Nargund
IPC分类号: A61K31/695 , C07D231/18 , A61K31/415 , C07D401/04 , C07D403/04 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/501 , C07F7/18 , C07D413/10 , A61K31/4245 , C07D401/14 , A61P19/02 , A61P3/10 , A61P21/00 , A61P29/00 , A61P25/06 , A61P25/28 , A61P25/16
CPC分类号: C07D471/04 , C07D231/18 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D413/10
摘要: The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease
摘要翻译: 本发明涉及可用作脂肪酸酰胺水解酶(FAAH)抑制剂的某些咪唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂,以及这些化合物及其制剂在治疗某些疾病,包括骨关节炎,类风湿性关节炎,糖尿病性神经病变,带状疱疹后神经痛,ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛,偏头痛,睡眠障碍,阿尔茨海默病和帕金森病
-
公开(公告)号:US20110144119A1
公开(公告)日:2011-06-16
申请号:US13057415
申请日:2009-07-30
申请人: Harry Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo
发明人: Harry Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo
IPC分类号: A61K31/501 , C07D413/14 , A61K31/497 , C07D413/04 , A61K31/444 , A61K31/4439 , A61K31/506 , C07D263/46 , A61K31/421 , C07D413/10 , A61K31/4245 , C07D413/12 , A61K31/4545 , C07D417/14 , A61K31/4725 , A61K31/4709 , A61P19/02 , A61P29/00 , A61P25/00 , A61P25/04 , A61P25/06 , A61P25/20 , A61P25/28 , A61P25/16
CPC分类号: C07D413/14 , C07D263/46 , C07D271/06 , C07D271/10 , C07D413/04 , C07D413/10 , C07D417/04 , C07D417/14
摘要: The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
摘要翻译: 本发明涉及可用作脂肪酸酰胺水解酶(FAAH)抑制剂的某些恶唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂,以及这些化合物及其制剂在治疗某些疾病,包括骨关节炎,类风湿性关节炎,糖尿病性神经病变,带状疱疹后神经痛,ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛,偏头痛,睡眠障碍,阿尔茨海默病和帕金森病。
-
公开(公告)号:US08673941B2
公开(公告)日:2014-03-18
申请号:US13057415
申请日:2009-07-30
申请人: Harry Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo
发明人: Harry Chobanian , Linus S. Lin , Ping Liu , Marc D. Chioda , Robert J. DeVita , Ravi P. Nargund , Yan Guo
CPC分类号: C07D413/14 , C07D263/46 , C07D271/06 , C07D271/10 , C07D413/04 , C07D413/10 , C07D417/04 , C07D417/14
摘要: The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.
摘要翻译: 本发明涉及可用作脂肪酸酰胺水解酶(FAAH)抑制剂的某些恶唑衍生物。 本发明还涉及包含这些化合物作为活性成分的药物制剂,以及这些化合物及其制剂在治疗某些疾病,包括骨关节炎,类风湿性关节炎,糖尿病性神经病变,带状疱疹后神经痛,ke肉肌痛和纤维肌痛等方面的用途。 作为急性疼痛,偏头痛,睡眠障碍,阿尔茨海默病和帕金森病。
-
公开(公告)号:US10000484B2
公开(公告)日:2018-06-19
申请号:US15101467
申请日:2014-12-16
申请人: MERCK SHARP & DOHME CORP. , Harry Chobanian , Barbara Pio , Yan Guo , Fa-Xiang Ding , Shuzhi Dong , Shawn P. Walsh , Jinlong Jiang , Dooseop Kim
发明人: Harry Chobanian , Barbara Pio , Yan Guo , Fa-Xiang Ding , Shuzhi Dong , Shawn P. Walsh , Jinlong Jiang , Dooseop Kim
IPC分类号: A61K31/4355 , A61K31/437 , A61K31/4985 , A61K31/519 , A61K31/55 , C07D471/04 , C07D487/04 , C07D498/04 , A61K31/401 , A61K31/4178 , A61K31/424 , A61K31/4422 , A61K31/496 , A61K31/4965 , A61K31/585 , A61K45/06
CPC分类号: C07D471/04 , A61K31/401 , A61K31/4178 , A61K31/424 , A61K31/437 , A61K31/4422 , A61K31/496 , A61K31/4965 , A61K31/4985 , A61K31/519 , A61K31/55 , A61K31/585 , A61K45/06 , C07D487/04 , C07D498/04 , A61K2300/00
摘要: The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
-
公开(公告)号:US10059667B2
公开(公告)日:2018-08-28
申请号:US15110894
申请日:2015-02-03
申请人: MERCK SHARP & DOHME CORP. , Harry Chobanian , Duane DeMong , Yan Guo , Zhiyong Hu , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao , Cangming Yang , Rui Zhang
发明人: Harry Chobanian , Duane DeMong , Yan Guo , Zhiyong Hu , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao , Cangming Yang
IPC分类号: C07D211/42 , A61K45/06 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , C07D231/20 , A61K31/4985 , C07D401/04 , C07D239/52 , C07C217/52 , C07D205/04 , C07D491/056 , C07D265/30 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/65 , C07D213/69 , C07D307/86 , C07D307/88 , C07C59/72 , C07D205/12 , C07D213/647
CPC分类号: C07D211/42 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , A61K31/4985 , A61K45/06 , C07C59/72 , C07C217/52 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07D205/04 , C07D205/12 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/647 , C07D213/65 , C07D213/69 , C07D231/20 , C07D239/52 , C07D265/30 , C07D307/86 , C07D307/88 , C07D401/04 , C07D491/056 , A61K2300/00
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US20160332968A1
公开(公告)日:2016-11-17
申请号:US15110894
申请日:2015-02-03
申请人: Harry CHOBANIAN , Duane DEMONG , Yan Guo , Zhiyong Hu , Barbara PIO , Christopher PLUMMER , Dong XIAO , Cangming YANG , Rui ZHANG , Merck Sharp & Dohme Corp. , Michael MILLER
发明人: Harry Chobanian , Duane DeMong , Yan Guo , Zhiyong Hu , Michael Miller , Barbara Pio , Christopher W. Plummer , Dong Xiao , Michael Yang
IPC分类号: C07D211/42 , C07D211/22 , C07D205/04 , C07D209/54 , C07D209/52 , C07D207/12 , C07D205/12 , C07C217/52 , C07D401/04 , C07D265/30 , C07C59/72 , C07D213/64 , C07D213/69 , C07D239/52 , C07D231/20 , C07D307/88 , C07D491/056 , C07D307/86 , C07D213/30 , C07D213/647 , C07D207/08
CPC分类号: C07D211/42 , A61K31/366 , A61K31/397 , A61K31/40 , A61K31/44 , A61K31/4985 , A61K45/06 , C07C59/72 , C07C217/52 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/10 , C07D205/04 , C07D205/12 , C07D207/08 , C07D207/10 , C07D207/12 , C07D209/52 , C07D209/54 , C07D211/22 , C07D213/30 , C07D213/64 , C07D213/647 , C07D213/65 , C07D213/69 , C07D231/20 , C07D239/52 , C07D265/30 , C07D307/86 , C07D307/88 , C07D401/04 , C07D491/056 , A61K2300/00
摘要: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
摘要翻译: 结构式(I)的新型化合物及其药学上可接受的盐是G蛋白偶联受体40(GPR40)的激动剂,可用于治疗,预防和抑制G蛋白偶联受体 受体40.本发明的化合物可用于治疗2型糖尿病,以及通常与该疾病相关的病症,包括肥胖症和脂质疾病,例如混合或糖尿病性血脂异常,高脂血症,高胆固醇血症和 高甘油三酯血症
-
公开(公告)号:US20160304515A1
公开(公告)日:2016-10-20
申请号:US15101467
申请日:2014-12-16
申请人: Harry CHOBANIAN , Barbara PIO , Yan GUO , Fa-Xiang DING , Shuzhi DONG , Shawn P. WALSH , Jinlong JIANG , Dooseop KIM , MERCK SHARP & DOHME CORP.
发明人: Harry Chobanian , Barbara Pio , Yan Guo , Fa-Xiang Ding , Shuzhi Dong , Shawn P. Walsh , Jinlong Jiang , Dooseop Kim
IPC分类号: C07D471/04 , A61K45/06 , A61K31/55 , C07D487/04 , A61K31/4985 , C07D498/04 , A61K31/519 , A61K31/437
CPC分类号: C07D471/04 , A61K31/401 , A61K31/4178 , A61K31/424 , A61K31/437 , A61K31/4422 , A61K31/496 , A61K31/4965 , A61K31/4985 , A61K31/519 , A61K31/55 , A61K31/585 , A61K45/06 , C07D487/04 , C07D498/04 , A61K2300/00
摘要: The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
-
公开(公告)号:US20150315141A1
公开(公告)日:2015-11-05
申请号:US14443470
申请日:2013-11-15
发明人: Harry Chobanian , Tesfaye Biftu , Barbara Pio , Zhicai Wu
IPC分类号: C07D207/16 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/06 , C07D207/34 , C07D401/06
CPC分类号: C07D207/16 , C07D207/34 , C07D401/06 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/06 , C07D417/06
摘要: Compounds of the invention, which may be useful in inhibiting thrombin and associated thrombotic occlusions, have the following structure: or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; R is a heterocycle, —(CR8R9)1-2NH2, or —(CR8R9)1-2OH, wherein R8 and R9, each time in which they occur, are independently H, C1-6 alkyl, —CH2F, —CHF2, CF3 or —CH2OH; W is a) —CHR1R2, where R1 is —C(CH3)3, and R2 is —(CH2)1-2OH, b) a 5- or 6-membered unsubstituted or substituted heterocycle having 1 or 2 heteroatoms selected from N and O, wherein substituted heterocycle is substituted with R3, c) a 9- or 10-membered unsubstituted or substituted heterocycle having 1 or 2 heteroatoms selected from N, O and S, wherein substituted heterocycle is mono-substituted with R3, or disubstituted with R3 and R4, or d) a 3-, 4-, or 5-membered carbocyclic ring which is unsubstituted, mono-substituted with R3, di-substituted with R3 and R4, or tri-substituted with R3, R4 and R5; R3 is —CF3, —COOH, —COOR7, —C(O)R6, —CH(OH)R6, —CH2R6, R6, =O, halogen, R7, —OH, —NH2, or —NHSO2R7; and R10 is H or C1-6 alkyl.
摘要翻译: 可用于抑制凝血酶和相关血栓闭塞的本发明化合物具有以下结构:或其药学上可接受的盐,其中m为0或1; R是杂环, - (CR 8 R 9)1-2 NH 2或 - (CR 8 R 9)1-2 OH,其中R 8和R 9各自独立地为H,C 1-6烷基,-CH 2 F,-CHF 2,CF 3 或-CH 2 OH; W是a)-CHR 1 R 2,其中R 1是-C(CH 3)3,并且R 2是 - (CH 2)1-2 OH,b)具有1或2个选自N的杂原子的5或6元未取代或取代的杂环, O,其中取代的杂环被R 3取代,c)具有1或2个选自N,O和S的杂原子的9或10元未取代或取代的杂环,其中取代的杂环被R 3单取代或被R 3二取代 和R 4,或d)未被取代的,被R 3和R 4二取代或被R3,R4和R5三取代的R3单取代的3-,4-或5-元碳环; R3是-CF3,-COOH,-COOR7,-C(O)R6,-CH(OH)R6,-CH2R6,R6,= O,卤素,R7,-OH,-NH2或-NHSO2R7; R 10为H或C 1-6烷基。
-
公开(公告)号:US09062070B2
公开(公告)日:2015-06-23
申请号:US14239649
申请日:2012-08-16
申请人: Alexander Pasternak , Timothy Blizzard , Harry Chobanian , Reynalda de Jesus , Fa-Xiang Ding , Shuzhi Dong , Candido Gude , Dooseop Kim , Haifeng Tang , Shawn Walsh , Barbara Pio , Jinlong Jiang
发明人: Alexander Pasternak , Timothy Blizzard , Harry Chobanian , Reynalda de Jesus , Fa-Xiang Ding , Shuzhi Dong , Candido Gude , Dooseop Kim , Haifeng Tang , Shawn Walsh , Barbara Pio , Jinlong Jiang
IPC分类号: C07D498/04 , A61K31/4985 , A61K31/5383 , A61K31/542 , A61K31/553 , A61K45/06 , C07D487/04 , C07D513/04
CPC分类号: C07D498/04 , A61K31/4985 , A61K31/5383 , A61K31/542 , A61K31/553 , A61K45/06 , C07D487/04 , C07D513/04
摘要: The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
摘要翻译: 本发明提供式Ia化合物及其药学上可接受的盐,它们是ROMK(Kir1.1)通道的抑制剂。 该化合物可以用作利尿剂和/或利尿钠剂,并且用于治疗和预防包括心血管疾病如高血压,心力衰竭以及与过量盐和水滞留有关的病症的医学病症。
-
公开(公告)号:US20140206618A1
公开(公告)日:2014-07-24
申请号:US14239649
申请日:2012-08-16
申请人: Alexander Pasternak , Timothy Blizzard , Harry Chobanian , Reynalda de Jesus , Fa-Xiang Ding , Shuzhi Dong , Candido Gude , Dooseop Kim , Haifeng Tang , Shawn Walsh , Barbara Pio , Jinlong Jiang
发明人: Alexander Pasternak , Timothy Blizzard , Harry Chobanian , Reynalda de Jesus , Fa-Xiang Ding , Shuzhi Dong , Candido Gude , Dooseop Kim , Haifeng Tang , Shawn Walsh , Barbara Pio , Jinlong Jiang
IPC分类号: C07D498/04 , A61K45/06 , A61K31/4985 , C07D513/04 , A61K31/542 , C07D487/04 , A61K31/5383 , A61K31/553
CPC分类号: C07D498/04 , A61K31/4985 , A61K31/5383 , A61K31/542 , A61K31/553 , A61K45/06 , C07D487/04 , C07D513/04
摘要: The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.
摘要翻译: 本发明提供式Ia化合物及其药学上可接受的盐,它们是ROMK(Kir1.1)通道的抑制剂。 这些化合物可以用作利尿剂和/或利尿钠剂,并且用于治疗和预防包括心血管疾病如高血压,心力衰竭以及与过量盐和保水有关的病症的医学病症。
-
-
-
-
-
-
-
-
-